GWM
ACOR

Geneos Wealth Management’s Acorda Therapeutics ACOR Stock Holding History

Geneos Wealth Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-83
Closed -$6K – 3035
2020
Q3 		$6K Hold
83
– – ﹤0.01% 2147
2020
Q2 		$7K Hold
83
– – ﹤0.01% 2060
2020
Q1 		$10K Buy
+83
New +$16.3K ﹤0.01% 1840

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geneos Wealth Management's ACOR Position: Q4 2020 in Review

Geneos Wealth Management sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 83 shares — an estimated $6K sold.

Geneos Wealth Management first reported a position in ACOR in Q1 2020 and held it in 3 quarters. The position peaked at $10K in Q1 2020. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • Geneos Wealth Management reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Geneos Wealth Management sold 83 Acorda Therapeutics shares in Q4 2020, an estimated $6K.
  • Geneos Wealth Management first reported a position in Acorda Therapeutics in Q1 2020 and held it in 3 quarters.
  • Geneos Wealth Management's Acorda Therapeutics position peaked at $10K in Q1 2020.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on Geneos Wealth Management's 13F filing for Q4 2020, filed 19 May 2021.